Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $237.84, but opened at $250.34. UCB shares last traded at $250.34, with a volume of 52 shares traded.
Wall Street Analysts Forecast Growth
UCBJF has been the topic of a number of analyst reports. Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group raised UCB to a “hold” rating in a report on Monday, August 3rd. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a research report on Wednesday. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, UCB has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on UCB
UCB Stock Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company’s 50 day simple moving average is $247.69 and its 200 day simple moving average is $275.86.
About UCB
UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.
The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).
Further Reading
- Five stocks we like better than UCB
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
- Synchrony Aces The Quarter As Credit Fears Fade
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
